A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

The inhibitor of apoptosis (IAP) family of antiapoptotic proteins has been identified as a target for small molecule inhibitors in cancer. Second mitochondrial-derived activator of caspases (SMAC) efficiently and naturally antagonizes IAPs, and preclinical studies have determined that SMAC mimetics have potent anticancer properties. Here, we report a first-in-human trial designed to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics/pharmacodynamics (PK/PD) of birinapant, a novel SMAC mimetic. Patients with advanced solid tumors or lymphoma were enrolled in a 3+3 dose escalation design with birinapant administered intravenously from 0.18 to 63 mg/m2 once weekly every 3 of 4 weeks. Fifty patients were enrolled to 12 dose cohorts. Birinapant 47 mg/m2 was determined to be the MTD. At 63 mg/m2, dose-limiting toxicities included headache, nausea, and vomiting. Two cases of Bell's palsy (grade 2) also occurred at 63 mg/m2. Birinapant had a plasma half-life of 30 to 35 hours and accumulated in tumor tissue. Birinapant suppressed cIAP1 and increased apoptosis in peripheral blood mononuclear cells and tumor tissue. Prolonged stable disease was observed in 3 patients: non–small cell lung cancer (5 months), colorectal cancer (5 months), and liposarcoma (9 months). Two patients with colorectal cancer had radiographic evidence of tumor shrinkage. In conclusion, birinapant was well tolerated with an MTD of 47 mg/m2 and exhibited favorable PK and PD properties. Several patients demonstrated stable disease and evidence of antitumor activity. These results support the ongoing clinical trials of birinapant in patients with cancer. Mol Cancer Ther; 14(11); 2569–75. ©2015 AACR.

[1]  C. Begley,et al.  Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis , 2015, Proceedings of the National Academy of Sciences.

[2]  S. Fulda.  Smac mimetics as IAP antagonists. , 2015, Seminars in cell & developmental biology.

[3]  Shaomeng Wang,et al.  Small-molecule SMAC mimetics as new cancer therapeutics. , 2014, Pharmacology & therapeutics.

[4]  D. Vaux,et al.  PHAGOCYTES , GRANULOCYTES , AND MYELOPOIESIS cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK 1-and RIPK 3-dependent manner , 2014 .

[5]  Yigong Shi,et al.  Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. , 2014, Journal of medicinal chemistry.

[6]  Yigong Shi,et al.  Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models , 2014, Molecular Cancer Therapeutics.

[7]  James M. Bogenberger,et al.  Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. , 2014, Journal of the National Cancer Institute.

[8]  H. Pehamberger,et al.  The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells , 2013, Clinical Cancer Research.

[9]  R. Korneluk,et al.  Modulation of immune signalling by inhibitors of apoptosis. , 2012, Trends in immunology.

[10]  P. LoRusso,et al.  Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[11]  D. Vaux,et al.  IAPs limit activation of RIP kinases by TNF receptor 1 during development , 2012, The EMBO journal.

[12]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[13]  Pascal Meier,et al.  IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer , 2010, Nature Reviews Cancer.

[14]  Clemencia Pinilla,et al.  Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. , 2008, Blood.

[15]  S. Baird,et al.  IAP-targeted therapies for cancer , 2008, Oncogene.

[16]  M. Bertrand,et al.  cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. , 2008, Molecular cell.

[17]  M. Irwin,et al.  Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. , 2008, The Journal of infectious diseases.

[18]  W. Sellers,et al.  A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. , 2007, Cancer research.

[19]  David L. Vaux,et al.  IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis , 2007, Cell.

[20]  Vishva M. Dixit,et al.  IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis , 2007, Cell.

[21]  R. Korneluk,et al.  The inhibitors of apoptosis (IAPs) as cancer targets , 2007, Apoptosis.

[22]  Xh Huang,et al.  Pharmacokinetic-Pharmacodynamic Modeling and Simulation. , 2007 .

[23]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Stephen W. Fesik,et al.  Promoting apoptosis as a strategy for cancer drug discovery , 2005, Nature Reviews Cancer.

[25]  M. Levin,et al.  Varicella-Zoster Virus DNA in Cells Isolated from Human Trigeminal Ganglia , 2003, Journal of Virology.

[26]  Robert L Moritz,et al.  Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.

[27]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[28]  R Simon,et al.  Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.

[29]  S. Condon.  The Discovery and Development of Smac Mimetics—Small-Molecule Antagonists of the Inhibitor of Apoptosis Proteins , 2011 .

[30]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[31]  Vinay Tergaonkar,et al.  IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. , 2007, Cell.

[32]  Vishva M Dixit,et al.  IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. , 2007, Cell.